#ThinkHand: people with PPMS need your help!
We need your help to raise awareness about hand function in MS #ThinkHand
In the last few days I have become increasingly anxious about the regulators, payers and healthcare professional letting down pwPPMS. Despite having the first positive trial of a DMT in PPMS there are many hurdles to overcome to get ocrelizumab to the people who need it, i.e. people with active PPMS.
It seems as if the wider community are fixated with the impact of ocrelizumab on lower limb function, i.e. compared to placebo it reduced EDSS progression and worsening of the Timed-25-Foot by ~25%. However, the elephant in the room is its impact on hand and arm function. In the ORATORIO study ocrelizumab reduced worsening of the 9-hole peg test by 45%, almost double the impact on lower limb function. These findings are entirely compatible with our length-dependent axonopathy hypothesis. In other words systems with shorter axons and more reserve will respond better to anti-inflammatory DMTs and in a shorter period of time. The upper limb findings of ocrelizumab are so important that I have asked Roche to seriously consider doing a trial in more advanced MS, including people in wheelchairs, to see if ocrelizumab can address this massive unmet need. Other surveys done as part of our #ThinkHand campaign have highlighted the importance of hand function for pwMS. When people lose the ability to walk their arms and hands become their legs and upper limb function keeps them independent.
The aim of this Blog is for the Barts and The London Neuroimmunology Group to update you on the latest research in MS with an emphasis on the research we are involved in. A major reason for maintaining the Blog is to thank the funders of our research. Funders encourage us to engage with the general public, people with MS and their families and other people with an interest in MS. We believe you have the right to know what we are spending your research money on! The purpose of our work is to improve our knowledge and understanding of MS with the goal of improving the lives of people living with this disease.
MS Unites is proud to have been approved by Barts MS to bring multiple sclerosis research & news to our global readership.